Is neutrophilic inflammation treatable in COVID-19?

Conrad, Catharina; Looney, Mark R.

doi:10.1016/s2213-2600(22)00293-4

Cited by 5 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various studies have identified the presence of high LDH levels as a prognostic biomarker with a high accuracy for predicting in-hospital mortality in severe and critically ill patients with COVID-19 [ [49] , [50] , [51] ] and a recent meta-analysis confirmed that LDH levels can be used as a COVID-19 severity marker and are a predictor of survival [ 52 ]. Finally, it has been recently argued that therapies specifically targeting neutrophilic inflammation in COVID-19 infection may have a positive effect, although no therapies have currently been investigated in large-scale clinical trials [ 53 ].…”

Section: Discussionmentioning

confidence: 99%

Pneumothorax in hospitalized COVID-19 patients with severe respiratory failure: Risk factors and outcome

Ragnoli

Cena²,

Radaeli

et al. 2023

Respiratory Medicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Pneumothorax in hospitalized COVID-19 patients with severe respiratory failure: Risk factors and outcome

Ragnoli

Cena²,

Radaeli

et al. 2023

Respiratory Medicine

View full text Add to dashboard Cite

“…Dapsone was used to be part of standard care in COVID-19 and related acute inflammatory lung dysfunctions [ 28 , 29 , 90 ]. Neutrophils have destructed a significant tissue element of COVID-19 lung [ [91] , [92] , [93] , [94] ]. On this basis, Badar et al.…”

Section: Treatment Mechanism Of Triadmentioning

confidence: 99%

Treatment mechanism of immune triad from the repurposing drug against COVID-19

Lee

2023

Translational Medicine of Aging

View full text Add to dashboard Cite

“…A significant tissue destructive element of COVID-19 lung dysfunction is wrought by neutrophils [ 22 , 23 , 24 , 25 ]. It was on this basis that dapsone was proposed in 2020 to be part of standard care in ARDS, including that during severe COVID-19 [ 3 , 4 , 5 , 26 ].…”

Section: Rationalementioning

confidence: 99%

Dapsone Lowers Neutrophil to Lymphocyte Ratio and Mortality in COVID-19 Patients Admitted to the ICU

Kanwar¹,

Khattak²,

Kast³

2022

IJMS

View full text Add to dashboard Cite

Some physicians use dapsone as part of the standard treatment of severe COVID-19 patients entering the ICU, though some do not. To obtain an indication of whether dapsone is helping or not, we undertook a retrospective chart review of 29 consecutive ICU COVID-19 patients receiving dapsone and 30 not receiving dapsone. As we previously reported, of those given dapsone, 9/29 (30%) died, while of those not given dapsone, 18/30 (60%) died. We looked back on that data set to determine if there might be basic laboratory findings in these patients that might give an indication of a mechanism by which dapsone was acting. We found that the neutrophil-to-lymphocyte ratio decreased in 48% of those given dapsone and in 30% of those not given dapsone. We concluded that dapsone might be lowering that ratio. We then reviewed collected data on neutrophil related inflammation pathways on which dapsone might act as presented here. As this was not a controlled study, many variables prevent drawing any conclusions from this work; a formal, randomized controlled study of dapsone in severe COVID-19 is warranted.

show abstract

Is neutrophilic inflammation treatable in COVID-19?

Cited by 5 publications

References 10 publications

Pneumothorax in hospitalized COVID-19 patients with severe respiratory failure: Risk factors and outcome

Pneumothorax in hospitalized COVID-19 patients with severe respiratory failure: Risk factors and outcome

Treatment mechanism of immune triad from the repurposing drug against COVID-19

Dapsone Lowers Neutrophil to Lymphocyte Ratio and Mortality in COVID-19 Patients Admitted to the ICU

Contact Info

Product

Resources

About